Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HL 2351

Next Previous
X
Search
Drug Profile

HL 2351

Alternative Names: GX P4; GX-P4 - Genexine; HL2351; Recombinant human interleukin-1 receptor antagonist hybrid Fc; rhIL-1Ra-hyFc

Latest Information Update: 31 Aug 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genexine
  • Developer Handok Inc
  • Class Anti-inflammatories; Antirheumatics; Biobetters; Biological proteins; Immunoglobulin Fc fragments; Immunoglobulin fusion proteins
  • Mechanism of Action Interleukin 1 receptor antagonists; Interleukin 6 inhibitors; Interleukin-8 expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cryopyrin-associated periodic syndromes; Rheumatoid arthritis

Most Recent Events

  • 31 Aug 2017 Discontinued - Phase-I for Rheumatoid arthritis in South Korea (SC)
  • 31 Aug 2017 Discontinued - Phase-II for Cryopyrin associated Periodic Syndromes (In children, In the elderly, In adults) in South Korea (unspecified route)
  • 03 Jan 2017 Handok Pharmaceuticals terminates a phase II trial in Cryopyrin associated Periodic Syndromes (In children, In adults, In the elderly) in South Korea due to difficulty in recruiting patients (NCT02853084)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top